Using a molecular modeling approach for Tau-binding sites, we modified our previously reported imaging agent, [125I]INFT, for the potential improvement of binding properties to Tau in an Alzheimer’s disease (AD) brain. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.